Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2005 4
2006 1
2007 3
2008 2
2009 2
2013 3
2014 2
2015 1
2016 2
2019 4
2020 1
2021 2
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications.
Sánchez-Fdez A, Matilla-Almazán S, Del Carmen S, Abad M, Arconada-Luque E, Jiménez-Suárez J, Chinchilla-Tábora LM, Ruíz-Hidalgo MJ, Sánchez-Prieto R, Pandiella A, Esparís-Ogando A. Sánchez-Fdez A, et al. Among authors: esparis ogando a. Exp Mol Med. 2023 Jun;55(6):1247-1257. doi: 10.1038/s12276-023-01008-x. Epub 2023 Jun 19. Exp Mol Med. 2023. PMID: 37332046 Free PMC article.
The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib.
Sánchez-Fdez A, Matilla-Almazán S, Montero JC, Del Carmen S, Abad M, García-Alonso S, Bhattacharya S, Calar K, de la Puente P, Ocaña A, Pandiella A, Esparís-Ogando A. Sánchez-Fdez A, et al. Among authors: esparis ogando a. Clin Transl Med. 2023 Apr;13(4):e1217. doi: 10.1002/ctm2.1217. Clin Transl Med. 2023. PMID: 37029785 Free PMC article.
ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology.
Arconada-Luque E, Jiménez-Suarez J, Pascual-Serra R, Nam-Cha SH, Moline T, Cimas FJ, Fliquete G, Ortega-Muelas M, Roche O, Fernández-Aroca DM, Muñoz Velasco R, García-Flores N, Garnés-García C, Sánchez-Fdez A, Matilla-Almazán S, Sánchez-Arévalo Lobo VJ, Hernández-Losa J, Belandia B, Pandiella A, Esparís-Ogando A, Ramón Y Cajal S, Del Peso L, Sánchez-Prieto R, Ruiz-Hidalgo MJ. Arconada-Luque E, et al. Among authors: esparis ogando a. Cancers (Basel). 2022 Jul 19;14(14):3509. doi: 10.3390/cancers14143509. Cancers (Basel). 2022. PMID: 35884568 Free PMC article.
Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21.
Tubita A, Lombardi Z, Tusa I, Lazzeretti A, Sgrignani G, Papini D, Menconi A, Gagliardi S, Lulli M, Dello Sbarba P, Esparís-Ogando A, Pandiella A, Stecca B, Rovida E. Tubita A, et al. Among authors: esparis ogando a. Cancer Res. 2022 Feb 1;82(3):447-457. doi: 10.1158/0008-5472.CAN-21-0993. Epub 2021 Nov 19. Cancer Res. 2022. PMID: 34799355 Free PMC article.
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
Nieto-Jimenez C, Galan-Moya EM, Corrales-Sanchez V, Noblejas-Lopez MDM, Burgos M, Domingo B, Montero JC, Gomez-Juarez M, Picazo-Martinez MG, Esparis-Ogando A, Pandiella A, Ocaña A. Nieto-Jimenez C, et al. Among authors: esparis ogando a. Cancer Lett. 2020 Oct 28;491:50-59. doi: 10.1016/j.canlet.2020.06.020. Epub 2020 Jul 28. Cancer Lett. 2020. PMID: 32735909 Free article.
A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors.
Pérez-Pena J, Tibor Fekete J, Páez R, Baliu-Piqué M, García-Saenz JÁ, García-Barberán V, Manzano A, Pérez-Segura P, Esparis-Ogando A, Pandiella A, Gyorffy B, Ocana A. Pérez-Pena J, et al. Among authors: esparis ogando a. Front Immunol. 2019 Dec 18;10:2802. doi: 10.3389/fimmu.2019.02802. eCollection 2019. Front Immunol. 2019. PMID: 31921107 Free PMC article.
32 results